These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 14533836)

  • 21. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine.
    Disel U; Gürkut O; Abali H; Kaleağasi H; Mertsoylu H; Ozyilkan O; Saif MW
    Cutan Ocul Toxicol; 2010 Jun; 29(2):140-2. PubMed ID: 20298142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onychomadesis and onycholysis associated with capecitabine.
    Chen GY; Chen YH; Hsu MM; Tsao CJ; Chen WC
    Br J Dermatol; 2001 Sep; 145(3):521-2. PubMed ID: 11531857
    [No Abstract]   [Full Text] [Related]  

  • 24. Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Jeung HC; Chung HC
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):141-3. PubMed ID: 20887492
    [No Abstract]   [Full Text] [Related]  

  • 25. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focal acral hyperpigmentation in a patient undergoing chemotherapy with capecitabine.
    Villalón G; Martín JM; Pinazo MI; Calduch L; Alonso V; Jordá E
    Am J Clin Dermatol; 2009; 10(4):261-3. PubMed ID: 19489659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
    Wang Y; Yang H; Wei JF; Meng L
    Curr Med Res Opin; 2012 Dec; 28(12):1911-9. PubMed ID: 23145857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
    Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
    Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.
    Sapp CM; DeSimone P
    Clin Colorectal Cancer; 2007 Jan; 6(5):382-5. PubMed ID: 17311704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
    Vickers MM; Easaw JC
    J Gastrointest Cancer; 2008; 39(1-4):141-3. PubMed ID: 19440857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine-induced hypertriglyceridemia and hyperglycemia: two cases.
    Duman BB; Paydas S; Tetiker T; Gunaldı M; Afsar CU; Erçolak V; Haksöyler V; Dilli MŞ
    Pharmacology; 2012; 90(3-4):212-5. PubMed ID: 23038659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
    Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
    Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of hand-foot syndrome in patient treated with capecitabine].
    Fujii C; Anami S; Fujino M; Yasui Y; Fujita M; Inoue M; Nakayama T; Kamigaki S; Tatsuta M; Furukawa H
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1357-60. PubMed ID: 18701848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
    Kara IO; Sahin B; Erkisi M
    Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
    Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
    Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine cardiac toxicity presenting as effort angina: a case report.
    Lestuzzi C; Crivellari D; Rigo F; Viel E; Meneguzzo N
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):700-3. PubMed ID: 20093950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lichenoid photosensitive eruption due to capecitabine chemotherapy for metastatic breast cancer.
    Hague JS; Ilchyshyn A
    Clin Exp Dermatol; 2007 Jan; 32(1):102-3. PubMed ID: 16879449
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer.
    Leonard RC
    Br J Cancer; 2001 Jun; 84(11):1437-42. PubMed ID: 11384089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.